Arcutis Biotherapeutics, Inc.
ARQT
$13.38
-$0.1222-0.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 196.01% | 412.79% | 451.92% | 546.92% | 675.58% |
| Total Other Revenue | -92.86% | -- | -- | -- | -- |
| Total Revenue | 32.84% | 427.58% | 17.44% | 494.57% | 1,682.42% |
| Cost of Revenue | 171.19% | 207.44% | 365.57% | 346.39% | 315.84% |
| Gross Profit | 23.11% | 471.41% | 6.30% | 520.62% | 2,217.97% |
| SG&A Expenses | 16.80% | 18.35% | 23.58% | 26.58% | 27.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.31% | 5.75% | 11.74% | 12.48% | 2.71% |
| Operating Income | 22.43% | 87.52% | -5.86% | 24.99% | 58.54% |
| Income Before Tax | 29.31% | 84.21% | 0.49% | 26.28% | 56.23% |
| Income Tax Expenses | -13.89% | 1,192.00% | -- | -- | -- |
| Earnings from Continuing Operations | 29.17% | 83.72% | 7.21% | 26.28% | 55.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.17% | 83.72% | 7.21% | 26.28% | 55.83% |
| EBIT | 22.43% | 87.52% | -5.86% | 24.99% | 58.54% |
| EBITDA | 31.56% | 88.20% | -3.06% | 25.09% | 58.81% |
| EPS Basic | 37.60% | 87.93% | 53.92% | 63.33% | 75.67% |
| Normalized Basic EPS | 37.71% | 88.29% | 50.57% | 63.33% | 75.89% |
| EPS Diluted | 37.60% | 87.93% | 53.92% | 63.33% | 75.67% |
| Normalized Diluted EPS | 37.71% | 88.29% | 50.57% | 63.33% | 75.89% |
| Average Basic Shares Outstanding | 13.50% | 34.93% | 101.37% | 101.01% | 81.54% |
| Average Diluted Shares Outstanding | 13.50% | 34.93% | 101.37% | 101.01% | 81.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |